“Secukinumab Sustains Individual Clinical Responses Over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S21. doi:10.25251/skin.2.supp.21.